Rivia secures EUR 3M Seed funding to revolutionize drug trial analytics for Biotechs
13.06.2024
Rivia, an innovative cloud-based platform designed exclusively for biotechnology firms to streamline the analysis of drug clinical trials, has announced the successful closure of a EUR 3 million Seed funding round. The investment will drive Rivia's mission to integrate advanced AI analytics and robust data infrastructure, promising to centralize and optimize clinical trial processes from a single, accessible location.
 Rivia's Co-Founders: CTO Tiago Kieliger and CEO Erik Scalfaro
|
 |
Founded by experienced biopharma professionals who understand the industry's challenges, Rivia is dedicated to developing user-friendly software tailored to the specific needs of Biotech companies. The ICT startup addresses a key inefficiency in the industry: While data collection methods have advanced, system integration capabilities and user-friendly web applications have not kept pace. As a result, data remains fragmented, and visualization tools are outdated. Rivia enables Biotechs to analyze trial data more effectively, leading to faster and more efficient pathways to market for their therapies. Rivia's impact is already evident with clients across Europe and the US, including Abcentra. Established in 2022, the startup currently has a team of seven.
Rivia has raised EUR 3M in a Seed funding round led by Speedinvest, with participation from Amino Collective and Nina Capital. The funds will be used to expand the engineering and client services teams and to advance product development. This will allow the company to fully leverage integrated trial data and solidify its position as the unified data platform for biopharma clinical trials.
Rivia won the first stage of Venture Kick in 2022.
Rivia's team
Rivia has raised EUR 3M in a Seed funding round led by Speedinvest, with participation from Amino Collective and Nina Capital. The funds will be used to expand the engineering and client services teams and to advance product development. This will allow the company to fully leverage integrated trial data and solidify its position as the unified data platform for biopharma clinical trials.
Rivia won the first stage of Venture Kick in 2022.
Rivia's team